Is Ozempic Semaglutide or Tirzepatide? The Definitive Answer and Why the Confusion Exists

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic contains semaglutide only. It is not tirzepatide and has never contained tirzepatide.
• Tirzepatide is sold under the brand names Mounjaro (for diabetes) and Zepbound (for weight loss), both manufactured by Eli Lilly.
• The confusion stems from overlapping marketing campaigns, similar injection devices, and the fact that both drugs are used for the same conditions (type 2 diabetes and obesity).
• Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP receptor agonist, making it structurally and mechanistically different.

Direct answer (40-60 words)

Ozempic is semaglutide, not tirzepatide. Ozempic and Wegovy both contain semaglutide and are manufactured by Novo Nordisk. Tirzepatide is a different medication sold as Mounjaro and Zepbound by Eli Lilly. The two drugs work through different receptor mechanisms, have different molecular structures, and are not interchangeable despite being used for similar conditions.

Table of contents

1. The one-sentence answer
2. Why the confusion exists: overlapping marketing and similar use cases
3. The structural and mechanistic differences between semaglutide and tirzepatide
4. Brand name breakdown: which drug is in which product
5. Clinical trial data: how the two drugs compare for weight loss and diabetes control
6. What most articles get wrong about GLP-1 medications
7. The decision tree: which medication matches your prescription
8. FormBlends clinical pattern: the most common mix-up we see
9. When switching from one to the other makes sense
10. The compounded medication question: does compounded semaglutide contain tirzepatide?
11. FAQ
12. Sources

The one-sentence answer

Ozempic is semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk and approved by the FDA in 2017 for type 2 diabetes.

Tirzepatide is a completely different molecule, a dual GLP-1/GIP receptor agonist manufactured by Eli Lilly and sold under the brand names Mounjaro (approved 2022 for diabetes) and Zepbound (approved 2023 for weight loss).

The two drugs are not interchangeable, do not contain the same active ingredient, and work through different receptor pathways despite both being injectable medications used for metabolic conditions.

Why the confusion exists: overlapping marketing and similar use cases

The confusion between Ozempic and tirzepatide is not random. Five factors drive the persistent misidentification:

1. Overlapping indications. Both semaglutide and tirzepatide are FDA-approved for type 2 diabetes. Both are used off-label (or in the case of Wegovy and Zepbound, on-label) for weight loss. Patients hear "diabetes injection for weight loss" and assume all such medications are the same drug.

2. Similar injection devices. Ozempic, Wegovy, Mounjaro, and Zepbound all use pre-filled, single-use injection pens. The devices look nearly identical: twist the dose selector, attach a needle, inject subcutaneously once weekly. The visual similarity reinforces the incorrect assumption that the contents are the same.

3. Concurrent marketing campaigns. Between 2022 and 2024, Novo Nordisk and Eli Lilly both ran aggressive direct-to-consumer advertising for their respective products. The campaigns emphasized weight loss, used similar visual language (before/after imagery, lifestyle transformation narratives), and aired during the same television programs. Patients saw both ads in the same commercial break and conflated the products.

4. Media coverage conflation. News articles about "the new weight-loss drugs" frequently discuss semaglutide and tirzepatide in the same paragraph without clearly distinguishing which brand name corresponds to which molecule. Headlines like "Ozempic and Mounjaro: What to Know" imply the drugs are variations of the same thing rather than distinct molecules.

5. Pharmacy and insurance documentation errors. We have seen prior authorization forms, insurance denial letters, and even pharmacy labels that incorrectly list "GLP-1 agonist" as the drug name rather than specifying semaglutide or tirzepatide. When the paperwork is vague, patients assume the drugs are interchangeable.

The result: roughly 30% of patients starting a GLP-1 medication cannot correctly name the active ingredient in their prescription when asked during follow-up visits (Kalarchian et al., Obesity, 2024).

The structural and mechanistic differences between semaglutide and tirzepatide

Semaglutide and tirzepatide are not variations of the same drug. They are different molecules with different structures and different mechanisms of action.

Semaglutide:

• Molecular structure: 31-amino-acid peptide analog of human GLP-1, modified with a C18 fatty acid side chain to extend half-life
• Mechanism: Selective GLP-1 receptor agonist. Binds to GLP-1 receptors in the pancreas, brain, stomach, and other tissues.
• Half-life: Approximately 7 days, enabling once-weekly dosing
• Receptor selectivity: GLP-1 only

Tirzepatide:

• Molecular structure: 39-amino-acid peptide with dual agonist activity, modified with a C20 fatty acid side chain
• Mechanism: Dual GLP-1 and GIP receptor agonist. Activates both GLP-1 receptors (similar to semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
• Half-life: Approximately 5 days, still compatible with once-weekly dosing
• Receptor selectivity: GLP-1 and GIP

The GIP receptor component is the critical difference. GIP is an incretin hormone that enhances insulin secretion, reduces glucagon, and may have additional effects on fat metabolism and energy expenditure. Activating both GLP-1 and GIP receptors produces greater weight loss in head-to-head trials than activating GLP-1 alone (Frias et al., New England Journal of Medicine, 2021).

The two drugs are structurally unrelated beyond both being peptide analogs. Calling tirzepatide "a type of semaglutide" is like calling ibuprofen "a type of acetaminophen" because both treat pain. Different molecules, different targets, different effects.

Brand name breakdown: which drug is in which product

The table below maps every FDA-approved brand name to its active ingredient and approved indication:

Brand name	Active ingredient	Manufacturer	FDA-approved indication	Typical dose range
Ozempic	Semaglutide	Novo Nordisk	Type 2 diabetes	0.5 mg to 2 mg weekly
Wegovy	Semaglutide	Novo Nordisk	Obesity (weight management)	2.4 mg weekly
Rybelsus	Semaglutide (oral)	Novo Nordisk	Type 2 diabetes	7 mg to 14 mg daily
Mounjaro	Tirzepatide	Eli Lilly	Type 2 diabetes	5 mg to 15 mg weekly
Zepbound	Tirzepatide	Eli Lilly	Obesity (weight management)	5 mg to 15 mg weekly

Key observations:

• Ozempic and Wegovy contain the same active ingredient (semaglutide) but are approved for different indications. Wegovy is dosed higher (2.4 mg) than the maximum Ozempic dose (2 mg), though the difference is marginal.
• Mounjaro and Zepbound contain the same active ingredient (tirzepatide) and use identical dose escalation schedules. The only difference is the FDA-approved indication printed on the label.
• Rybelsus is the only oral GLP-1 medication on the U.S. market. It contains semaglutide in a tablet formulation with an absorption enhancer. Oral semaglutide has lower bioavailability than injectable semaglutide, requiring daily dosing.

If your prescription says "Ozempic," you are receiving semaglutide. If it says "Mounjaro" or "Zepbound," you are receiving tirzepatide. The active ingredient is printed on the carton and in the prescribing information insert inside the box.

Clinical trial data: how the two drugs compare for weight loss and diabetes control

The best head-to-head comparison comes from the SURPASS-2 trial, which directly compared tirzepatide to semaglutide in patients with type 2 diabetes (Frias et al., New England Journal of Medicine, 2021). The trial enrolled 1,879 patients and ran for 40 weeks.

Weight loss results (SURPASS-2):

Treatment	Average weight loss	Percentage achieving ≥10% weight loss
Tirzepatide 5 mg	7.6 kg (16.8 lbs)	31%
Tirzepatide 10 mg	9.3 kg (20.5 lbs)	51%
Tirzepatide 15 mg	11.2 kg (24.7 lbs)	63%
Semaglutide 1 mg	5.7 kg (12.6 lbs)	22%

Tirzepatide at the 15 mg dose produced nearly double the weight loss of semaglutide 1 mg. The comparison is imperfect because the trial used semaglutide 1 mg (the typical diabetes dose) rather than 2.4 mg (the weight-loss dose used in Wegovy). A true head-to-head trial comparing tirzepatide 15 mg to semaglutide 2.4 mg has not been published as of April 2026.

A1C reduction (SURPASS-2):

Treatment	Average A1C reduction	Percentage achieving A1C <7%
Tirzepatide 5 mg	2.01%	79%
Tirzepatide 10 mg	2.24%	83%
Tirzepatide 15 mg	2.30%	86%
Semaglutide 1 mg	1.86%	72%

Tirzepatide produced statistically superior A1C reduction at all three doses compared to semaglutide 1 mg. The difference is clinically meaningful: an additional 0.4% A1C reduction translates to lower long-term microvascular complication risk.

For weight loss specifically, the STEP 1 trial (semaglutide 2.4 mg for obesity) and SURMOUNT-1 trial (tirzepatide for obesity) provide indirect comparison:

• STEP 1: Semaglutide 2.4 mg produced 14.9% total body weight loss over 68 weeks (Wilding et al., New England Journal of Medicine, 2021).
• SURMOUNT-1: Tirzepatide 15 mg produced 20.9% total body weight loss over 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022).

The trials are not directly comparable (different populations, slightly different durations), but the signal is consistent: tirzepatide produces greater weight loss than semaglutide at maximum approved doses.

Side effect comparison:

Both drugs share a similar side effect profile: nausea, vomiting, diarrhea, constipation, and abdominal pain are the most common. The SURPASS-2 trial found slightly higher nausea rates with tirzepatide 15 mg (21%) than semaglutide 1 mg (18%), but the difference was not statistically significant. Discontinuation rates due to side effects were comparable (6% for tirzepatide 15 mg, 4% for semaglutide 1 mg).

What most articles get wrong about GLP-1 medications

The most common error in published content about GLP-1 medications is the claim that "Ozempic, Wegovy, Mounjaro, and Zepbound all work the same way."

This is false. Semaglutide-based products (Ozempic, Wegovy) work through GLP-1 receptor activation only. Tirzepatide-based products (Mounjaro, Zepbound) work through dual GLP-1 and GIP receptor activation. The mechanisms overlap but are not identical.

The error matters because it leads patients to believe the drugs are interchangeable. We see this play out in three ways:

1. Insurance denial confusion. A patient is prescribed Wegovy. Insurance denies coverage. The patient asks, "Can I just get Mounjaro instead since they're the same thing?" No. Different drug, different prior authorization requirements, different formulary tier. Switching requires a new prescription and a separate prior authorization process.

2. Compounded medication misunderstanding. A patient sees "compounded semaglutide" advertised and assumes it will produce the same results as the tirzepatide their friend is taking. It will not. Compounded semaglutide is semaglutide. Compounded tirzepatide is tirzepatide. The active ingredient determines the outcome, not the fact that both are compounded.

3. Dose equivalency errors. A patient switching from semaglutide 1 mg to tirzepatide asks, "What's the equivalent tirzepatide dose?" There is no direct equivalency. The drugs work through different mechanisms. Tirzepatide dosing starts at 2.5 mg and escalates independently of prior semaglutide dose. Assuming equivalency leads to underdosing or overdosing.

The correct framing: semaglutide and tirzepatide are both incretin-based therapies used for similar conditions, but they are distinct medications with different structures, mechanisms, and clinical profiles. Treat them as you would treat two different antibiotics in the same class: related, but not interchangeable.

The decision tree: which medication matches your prescription

Use this flow to identify which medication you are taking:

Step 1: Check the brand name on your prescription or medication box.

• If it says Ozempic or Wegovy, you have semaglutide.
• If it says Mounjaro or Zepbound, you have tirzepatide.
• If it says Rybelsus, you have oral semaglutide.
• If it says compounded semaglutide, you have semaglutide prepared by a compounding pharmacy.
• If it says compounded tirzepatide, you have tirzepatide prepared by a compounding pharmacy.

Step 2: If the brand name is unclear or the prescription says "GLP-1 agonist," check the dosing schedule.

• Once-weekly injection, doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg: Semaglutide.
• Once-weekly injection, doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg: Tirzepatide.
• Daily oral tablet, doses of 3 mg, 7 mg, or 14 mg: Oral semaglutide (Rybelsus).

Step 3: If you are still uncertain, check the prescribing information insert.

Every FDA-approved medication includes a prescribing information insert in the box. The first page lists the active ingredient under "Description." Compounded medications include a pharmacy-generated label listing the active ingredient and concentration.

Step 4: If the prescription was written as "semaglutide" or "tirzepatide" without a brand name, ask your pharmacy which manufacturer supplied the medication.

• Novo Nordisk supplies semaglutide (Ozempic, Wegovy, Rybelsus).
• Eli Lilly supplies tirzepatide (Mounjaro, Zepbound).
• Compounding pharmacies supply compounded versions of both.

If you cannot determine which medication you are taking after following this tree, contact your prescribing provider or the dispensing pharmacy. Do not assume based on the condition being treated. Both drugs are used for diabetes and weight loss.

FormBlends clinical pattern: the most common mix-up we see

Across our patient population, the most common confusion pattern is not mistaking Ozempic for tirzepatide. It is mistaking compounded semaglutide for brand-name Ozempic and assuming they are clinically identical.

The pattern looks like this: a patient starts brand-name Ozempic through insurance. The insurance stops covering it after three months or raises the copay to $900 per month. The patient switches to compounded semaglutide through a telehealth platform. The patient then asks, "Why does my new Ozempic come in a vial instead of a pen?"

The answer: it is not Ozempic. It is compounded semaglutide. Same active ingredient, different formulation, different delivery system, different regulatory pathway.

Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. It does not undergo the same manufacturing controls, stability testing, or batch consistency verification as FDA-approved Ozempic.

That does not mean compounded semaglutide is unsafe or ineffective. It means it is a different product. The clinical outcomes are generally comparable when the compounding pharmacy follows USP 795 and USP 797 standards, but the products are not interchangeable from a regulatory or insurance perspective.

The same applies to compounded tirzepatide vs. brand-name Mounjaro or Zepbound. Compounded tirzepatide contains tirzepatide. Brand-name products contain tirzepatide. Same active ingredient, different regulatory status.

The second most common mix-up: patients who were told by a friend or online forum that "Mounjaro is just stronger Ozempic" and expect to switch from semaglutide to tirzepatide without retitrating. Tirzepatide is not stronger semaglutide. It is a different drug. Switching requires starting at the tirzepatide starting dose (2.5 mg) and escalating over 16 to 20 weeks, even if you were previously stable on semaglutide 2.4 mg.

We see this pattern most often in patients switching due to insurance coverage changes or medication shortages. The expectation is seamless transition. The reality is a new titration schedule with a new side effect profile.

When switching from one to the other makes sense

Switching from semaglutide to tirzepatide, or vice versa, is common. The decision is usually driven by one of four factors:

1. Inadequate weight loss on semaglutide. If a patient reaches semaglutide 2.4 mg, tolerates it well, but plateaus at 8% to 10% total body weight loss when the goal is 15% or more, switching to tirzepatide is reasonable. The SURMOUNT-1 data suggests tirzepatide produces an additional 6% body weight loss on average compared to semaglutide 2.4 mg.

2. Insurance coverage changes. Insurance formularies change quarterly. A patient stable on Wegovy may find it is no longer covered and Zepbound is now preferred, or vice versa. Switching is a coverage decision, not a clinical one.

3. Medication shortages. The FDA shortage list has included both semaglutide and tirzepatide products intermittently since 2022. When one is unavailable, switching to the other (or to a compounded version) maintains continuity of care.

4. Side effect profile differences. Some patients tolerate semaglutide better than tirzepatide, or vice versa. Nausea, vomiting, and gastrointestinal side effects vary by individual. If side effects are intolerable on one drug, trying the other is a reasonable next step.

The switching protocol:

Switching from semaglutide to tirzepatide (or the reverse) is not a direct dose conversion. The standard approach:

• Stop the current medication. Allow one week for clearance (both drugs have half-lives of 5 to 7 days, so one week reduces circulating levels by roughly 50%).
• Start the new medication at its standard starting dose. For tirzepatide, that is 2.5 mg weekly. For semaglutide, that is 0.25 mg weekly.
• Escalate per the standard titration schedule. Do not skip steps. The fact that you tolerated semaglutide 2.4 mg does not mean you can start tirzepatide at 10 mg.

Some providers use an accelerated titration schedule for patients switching between drugs (escalating every 2 weeks instead of every 4 weeks), but this is off-label and increases side effect risk.

The one scenario where switching does not make sense: switching back and forth repeatedly due to cost or availability. Each switch requires retitration, which means 12 to 20 weeks of suboptimal dosing and recurrent side effects. If cost or availability is unstable, compounded versions of the same drug provide more continuity than switching between semaglutide and tirzepatide every few months.

The compounded medication question: does compounded semaglutide contain tirzepatide?

No. Compounded semaglutide contains semaglutide. Compounded tirzepatide contains tirzepatide. Compounding pharmacies do not mix the two drugs, and no compounded formulation contains both semaglutide and tirzepatide in a single vial.

The confusion arises because some compounded formulations include additional ingredients beyond the active drug:

• Vitamin B12 (cyanocobalamin). Added to some compounded semaglutide and tirzepatide formulations to address potential B12 deficiency during weight loss. The B12 does not change the fact that the active ingredient is semaglutide or tirzepatide.
• Glycine or mannitol. Used as stabilizers or bulking agents in lyophilized (freeze-dried) formulations. These are inactive ingredients.
• Bacteriostatic water or sodium chloride. Used as the reconstitution solution for lyophilized formulations.

If you are prescribed "compounded semaglutide with B12," the active weight-loss ingredient is semaglutide. The B12 is supplemental. If you are prescribed "compounded tirzepatide," the active ingredient is tirzepatide, period.

Compounded formulations are required to list the active ingredient(s) on the pharmacy label. If the label says "semaglutide 2.5 mg/0.5 mL," you are receiving semaglutide. If it says "tirzepatide 5 mg/0.5 mL," you are receiving tirzepatide.

One edge case: some patients receive compounded semaglutide and separately receive compounded B6 or L-carnitine injections as part of a weight-loss protocol. These are separate injections, not combined formulations. The semaglutide vial contains semaglutide. The B6 vial contains B6. They are not mixed.

The regulatory and legal distinction: why it matters beyond clinical care

The distinction between semaglutide and tirzepatide has legal and regulatory consequences beyond which drug works better.

Patent and exclusivity. Novo Nordisk holds patents on semaglutide formulations through 2031. Eli Lilly holds patents on tirzepatide through 2036. The two drugs are protected by different patent estates. Generic semaglutide and generic tirzepatide will not be available until those patents expire.

FDA approval dates and indications. Ozempic was approved in 2017. Wegovy was approved in 2021. Mounjaro was approved in 2022. Zepbound was approved in 2023. The staggered approval dates affect insurance coverage, prior authorization requirements, and which drug is considered "first-line" in clinical guidelines.

Compounding legality during shortages. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare copies of FDA-approved drugs only when the drug is on the FDA shortage list. As of April 2026, both semaglutide and tirzepatide have been listed intermittently. When a drug is removed from the shortage list, compounding it becomes legally questionable. Patients need to know which specific drug they are taking to understand whether their compounded prescription remains legal.

Insurance formulary placement. Most insurance plans place semaglutide and tirzepatide on different formulary tiers. A plan might cover Ozempic as a Tier 2 drug (moderate copay) and Mounjaro as a Tier 3 drug (high copay), or vice versa. Assuming the drugs are interchangeable leads to surprise denials and out-of-pocket costs.

Prior authorization criteria. Insurance prior authorization forms ask for the specific drug name, not "GLP-1 agonist." A prior authorization approved for semaglutide does not cover a tirzepatide prescription. Patients switching drugs must submit a new prior authorization, which can delay treatment by 2 to 6 weeks.

The regulatory distinction is not academic. It determines whether your prescription is legal, whether your insurance will pay, and whether your pharmacy can fill it.

FAQ

Is Ozempic the same as tirzepatide? No. Ozempic contains semaglutide, not tirzepatide. Ozempic is manufactured by Novo Nordisk and approved for type 2 diabetes. Tirzepatide is a different drug sold as Mounjaro and Zepbound by Eli Lilly.

What is the difference between semaglutide and tirzepatide? Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist. Tirzepatide activates an additional receptor (GIP) that semaglutide does not, which produces greater weight loss in clinical trials.

Does Ozempic contain tirzepatide? No. Ozempic contains only semaglutide. It does not contain tirzepatide or any other active ingredient.

Which is better for weight loss, Ozempic or tirzepatide? Tirzepatide produces greater average weight loss than semaglutide in head-to-head trials. Tirzepatide 15 mg produced 20.9% total body weight loss in SURMOUNT-1. Semaglutide 2.4 mg (Wegovy) produced 14.9% in STEP 1. Individual results vary.

Can I switch from Ozempic to Mounjaro? Yes, but it requires a new prescription and retitration. You cannot directly convert doses. Stop Ozempic, wait one week, then start Mounjaro at 2.5 mg and escalate per the standard schedule.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide and Ozempic both contain semaglutide, but they are not identical products. Ozempic is FDA-approved and manufactured under FDA oversight. Compounded semaglutide is prepared by a state-licensed pharmacy and is not FDA-approved.

Does Wegovy contain tirzepatide? No. Wegovy contains semaglutide, the same active ingredient as Ozempic. Wegovy is dosed at 2.4 mg weekly for weight loss. Tirzepatide is sold as Zepbound for weight loss.

Are Mounjaro and Zepbound the same drug? Yes. Both contain tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight loss. The active ingredient and dosing schedule are identical.

Why do people confuse Ozempic with tirzepatide? Both drugs are weekly injections used for diabetes and weight loss. Both have been heavily marketed since 2022. The similar use cases, overlapping marketing, and identical-looking injection pens cause confusion.

Is tirzepatide stronger than semaglutide? Tirzepatide produces greater weight loss and A1C reduction in clinical trials, but "stronger" is not the right framing. Tirzepatide works through a different mechanism (dual GLP-1/GIP agonism) rather than being a higher-potency version of semaglutide.

Can I take Ozempic and tirzepatide together? No. Taking both drugs simultaneously is not recommended and is not supported by clinical trial data. The drugs work through overlapping pathways, and combining them increases side effect risk without clear additional benefit.

How do I know if my prescription is semaglutide or tirzepatide? Check the brand name on the prescription or medication box. Ozempic, Wegovy, and Rybelsus contain semaglutide. Mounjaro and Zepbound contain tirzepatide. Compounded prescriptions will specify "compounded semaglutide" or "compounded tirzepatide."

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): gastric emptying substudy. Diabetes Care. 2023.
5. Kalarchian MA et al. Patient knowledge and perceptions of GLP-1 receptor agonist therapy. Obesity. 2024.
6. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
7. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018.
8. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
9. Baggio LL et al. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
14. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2017, revised 2024.
15. Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. 2022, revised 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.